Trevi Therapeutics (TRVI) Tops Q3 EPS by 6c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Can global equities keep rising? UBS sees these factors driving upside
• Corpay agrees to $100M FTC settlement over marketing practices